161 related articles for article (PubMed ID: 12531222)
1. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Bolaños-Meade J; Karp JE; Guo C; Sarkodee-Adoo CB; Rapoport AP; Tidwell ML; Buddharaju LN; Chen TT
Leuk Res; 2003 Apr; 27(4):313-21. PubMed ID: 12531222
[TBL] [Abstract][Full Text] [Related]
2. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
[TBL] [Abstract][Full Text] [Related]
3. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
[TBL] [Abstract][Full Text] [Related]
4. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
5. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
6. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
Ustün C; Beksac M; Dalva K; Koc H; Konuk N; Ilhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M
Med Oncol; 2002; 19(1):59-67. PubMed ID: 12025892
[TBL] [Abstract][Full Text] [Related]
7. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Hartmann F; Jacobs G; Gotto H; Schwamborn J; Pfreundschuh M
Leuk Lymphoma; 2001 Jul; 42(3):347-55. PubMed ID: 11699399
[TBL] [Abstract][Full Text] [Related]
8. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Van Der Jagt R; Robinson KS; Belch A; Yetisir E; Wells G; Larratt L; Shustik C; Gluck S; Stewart K; Sheridan D;
Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.
Milligan DW; Wheatley K; Littlewood T; Craig JI; Burnett AK;
Blood; 2006 Jun; 107(12):4614-22. PubMed ID: 16484584
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
12. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
14. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Beksaç M; Arslan O; Koç H; Akan H; Ilhan O; Arat M; Ozcan M; Gürman G; Konuk N; Uysal A
Med Oncol; 1998 Sep; 15(3):183-90. PubMed ID: 9819795
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.
Bassan R; Intermesoli T; Masciulli A; Pavoni C; Boschini C; Gianfaldoni G; Marmont F; Cavattoni I; Mattei D; Terruzzi E; De Paoli L; Cattaneo C; Borlenghi E; Ciceri F; Bernardi M; Scattolin AM; Todisco E; Campiotti L; Corradini P; Cortelezzi A; Ferrero D; Zanghì P; Oldani E; Spinelli O; Audisio E; Cortelazzo S; Bosi A; Falini B; Pogliani EM; Rambaldi A
Blood Adv; 2019 Apr; 3(7):1103-1117. PubMed ID: 30948365
[TBL] [Abstract][Full Text] [Related]
16. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Montillo M; Ricci F; Tedeschi A; Cafro AM; Nosari AM; Nichelatti M; Marbello L; Morra E
Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
[TBL] [Abstract][Full Text] [Related]
17. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
De Witte T; Suciu S; Selleslag D; Labar B; Roozendaal K; Zittoun R; Ribeiro M; Kurstjens R; Hayat M; Dardenne M; Solbu G; Muus P
Ann Hematol; 1996 Mar; 72(3):119-24. PubMed ID: 8766252
[TBL] [Abstract][Full Text] [Related]
18. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
